{"id":221064,"date":"2026-08-27T13:19:28","date_gmt":"2026-08-27T07:49:28","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=221064"},"modified":"2026-08-27T13:19:30","modified_gmt":"2026-08-27T07:49:30","slug":"api-and-pharma-ingredients-stocks-long-term-growth-potential","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/api-and-pharma-ingredients-stocks-long-term-growth-potential\/","title":{"rendered":"4 API and Pharma Ingredients Stocks with Long-Term Growth Potential"},"content":{"rendered":"

Neuland Laboratories ROE is 19.42%. Laurus Labs PE stands at 93.56. All four supply active pharmaceutical ingredients to domestic and global drug makers. Figures as of 27 August 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

API and pharma ingredients stocks span companies manufacturing active pharmaceutical ingredients and intermediates for domestic and global generic drug makers. Laurus Labs, Aarti Drugs, Neuland Laboratories and Granules India each hold different product portfolios and customer relationships within the API manufacturing value chain, from antiretroviral drugs to contract development services. Multibagger outcomes in API and pharma ingredients stocks have often followed regulatory approvals and contract manufacturing deal wins. Investors should weigh product portfolio, regulatory track record and valuation before adding these API and pharma ingredients stocks to a long term portfolio.<\/p>\n<\/div>\n

API and pharma ingredients stocks give investors exposure to India’s active pharmaceutical ingredient manufacturing industry, which supplies both domestic generic drug makers and global pharmaceutical companies. The sector depends heavily on regulatory approvals from health authorities in key export markets.<\/p>\n

The four companies covered here, Laurus Labs, Aarti Drugs, Neuland Laboratories and Granules India, hold different product portfolios spanning antiretroviral APIs, generic ingredients and contract development services. Because API and pharma ingredients stocks depend on regulatory track records and customer relationships specific to each company, evaluating them properly means understanding each company’s specific product portfolio rather than treating the sector as a single API demand play.<\/p>\n

The market data referenced in this article, including current price, market capitalisation and valuation ratios, reflects figures available at the time of writing on 27 August 2026 and will change with subsequent market movements. Readers should verify current prices before making any investment decision.<\/em><\/p>\n

Click Here – Get Free Investment Predictions<\/a><\/strong><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n